TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01981746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with ropivacaine 0.1%
Description: US-guided adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with ropivacaine 0.1%
Description: US-guided adductor canal block
Study: NCT02761317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard preparation (2L PEG-ELS)
Description: Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)
Description: Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
Study: NCT02969590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin
Description: Synthetic progestin to assess effects on cervical mucus.
Study: NCT02366429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for antenatal depression
Description: Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual provided at antenatal clinics and other health care instances
Study: NCT00529139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard extended dialysis
Description: Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensified extended dialysis
Description: Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
Study: NCT04384380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Description: Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
Study: NCT02761317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-volume preparation (4L PEG-ELS)
Description: Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
Study: NCT05026372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Compassion (MC)
Description: The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Study: NCT04431128

Intervention type: BEHAVIORAL
Intervention: infant feeding position
Description: correlation with allergy, GER or feeding position

Intervention type: BEHAVIORAL
Intervention: infant feeding position
Description: correlation with allergy, GER or feeding position
Study: NCT02773732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 MG
Description: 750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 MG
Description: 1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: 500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
Study: NCT00637104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mar-Tyn TiN coated Co-Cr Numen stent implant
Description: Implant of the Mar-tyn TiN coated stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vision Co-Cr stent implant
Description: Implant of the Vision stent
Study: NCT02495623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 21 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 42 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01243775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotaxel
Description: 60 mg/m2 3 weekly (day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belloxa
Description: 70 mg/m2 3 weekly (day 2)
Study: NCT03916783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination intervention
Description: The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.
Study: NCT00264550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants will receive methotrexate capsules weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive methotrexate capsules weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive methotrexate capsules weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
Study: NCT01959594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PF-06412562
Description: oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg PF-06412562
Description: oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
Study: NCT00264550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Participants will receive placebo capsules weekly
Study: NCT01794559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEER Interactive Report
Description: The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
Study: NCT05026372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Gratitude (MG)
Description: The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Study: NCT01959594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 TBD mg
Description: oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 TBD mg
Description: oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
Study: NCT02926690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167PO
Description: Single arm, no competitor
Study: NCT05026372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Value-Based Living (MV)
Description: The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Study: NCT03703310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib Topical Gel, 2%
Description: Patidegib Topical Gel, 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patidegib Topical Gel, Vehicle
Description: Patidegib Topical Gel, Vehicle
Study: NCT02811913

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS

Intervention type: OTHER
Group type: OTHER
Intervention: peripheral sensory stimulation
Description: peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS

Intervention type: OTHER
Group type: OTHER
Intervention: peripheral sensory stimulation
Description: peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS

Intervention type: OTHER
Group type: OTHER
Intervention: peripheral sensory stimulation
Description: peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
Study: NCT04104685

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FCD105
Description: Experimental combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Minocycline Foam
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Adapalene Foam
Description: Active Comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Placebo
Study: NCT02969096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Cryoablation Therapy
Description: A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
Study: NCT03315338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 25 mg
Description: CORT118335 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Oral Tablet
Description: Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Oral Tablet
Description: Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Oral Tablet
Description: Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 75 g in 300 mL solution, orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 75 g in 300 mL solution, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: 75 g in 300 mL solution, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.
Study: NCT02223611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 capsule
Description: Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
Study: NCT03315338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 75mg
Description: CORT118335 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 225mg
Description: CORT118335 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 675mg
Description: CORT118335 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 675mg
Description: CORT118335 is supplied as capsules for oral dosing
Study: NCT00258128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Active
Study: NCT03315338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 600mg
Description: CORT118335 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 600mg
Description: CORT118335 is supplied as capsules for oral dosing
Study: NCT00258128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for salslate, used only in the third trial
Study: NCT03315338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 630mg
Description: CORT118335 is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 375mg
Description: CORT118335 is supplied as capsules for oral dosing
Study: NCT04103541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-Colombia
Description: The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
Study: NCT02462291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Environmental therapy
Description: The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
Study: NCT04045483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality based cognitive training
Description: The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
Study: NCT00131131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT02994043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Relapse Prevention Therapy
Description: An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Therapy
Description: An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
Study: NCT01233739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Description: Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
Study: NCT04839848

Intervention type: DEVICE
Intervention: Lichtenstein mesh repair
Description: A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures

Intervention type: DEVICE
Intervention: Lichtenstein mesh repair
Description: A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures

Intervention type: DEVICE
Intervention: Lichtenstein mesh repair
Description: A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures

Intervention type: DEVICE
Intervention: Lichtenstein mesh repair
Description: A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures

Intervention type: DEVICE
Intervention: Lichtenstein mesh repair
Description: A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
Study: NCT01632241

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Placebo plus standard therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Description: Belimumab 10mg/kg plus standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Study: NCT02024022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard approach
Description: bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized approach
Study: NCT00497237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone plus formoterol fixed combination
Description: 100+6 pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone plus salmeterol fixed combination
Description: diskus 250/50
Study: NCT02836873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (inactive) tablet to match the active comparator
Study: NCT03691350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with bronchoalveolar lavage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with bronchoalveolar lavage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with bronchoalveolar lavage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with bronchoalveolar lavage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Smoke usual brand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Smoke SREC with nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Smoke SREC without nictoine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Receive NRT comprising patch, gum, or lozenge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies